HEART AND LUNG THERAPIES

Xenios AG a Fresenius Medical Care company is a pioneer in extracorporeal heart & lung support.

Our dedication to improve patients’ lives, drives us to constantly develop high-quality products and application-related service excellence, which allow to replace standard therapies with superior extracorporeal solutions.

On that account Xenios stands for a change of paradigm in intensive-care medicine and forms a significant part of FME’s holistic multi-organ approach.

Time to Heal - Novalung ECMO therapy

HEART THERAPIES

Medos is your partner experienced in cardiopulmonary solutions for more than 30 years: highly skilled employees and high-quality manufacturing, for the benefit of cardiac surgeons, perfusionists and patients.

SYNCHRONIZED CARDIAC SUPPORT

Synchronized Cardiac Support is a new mechanical circulatory support method that adapts to the patient’s heart rhythm.
Pulsatility is closer to human physiology than continuous flow. The therapeutic goals are myocardial recovery and adequate organ perfusion.

LUNG THERAPIES

Novalung therapy allows to mitigate, prevent or replace mechanical ventilation by extracorporeal gas exchange. It enables caregivers to give the lung time to heal and change the therapy environment in the ICU – from CO2 removal to full oxygenation.

BY
YOUR
SIDE

CLINICAL SUPPORT

Our internationally acclaimed clinical support team accompanies the clinical application of all Xenios products. Our specialists trained in intensive care are available on a telephone hotline. The clinical support team also provides support on-site in hospitals during initial applications of Novalung products and offers customized training courses.

CAMPUS
LEARNING WITH XENIOS

LOOKING FOR FURTHER THERAPY- AND XENIOS PRODUCT INFORMATION?

Join our Xenios Campus to explore various eLearnings for example expert interviews, best-practice-cases, medical knowledge, hands-on-tutorials, priming instructions and more. Of course, free of charge and without obligation.

News
News

Xenios AG receives approval in China for ECMO devices

13. July 2021

Xenios AG, a Fresenius Medical Care company, has received approval from the National Medical Products Administration (NMPA) in China for the Xenios console and patient kits for ECMO therapy. In early May, Xenios AG, a Fresenius Medical Care company, received approval for two patient kits in China. It follows NMPA’s ...

News

EuroELSO 2021 Virtual Congress

28. April 2021

Meet Fresenius Medical Care Heart & Lung (Xenios) at EuroELSO 2021 and join our symposium! In our virtual ICU, you will learn about our products and therapies directly on a VV ECMO patient case. Talk to our experts via text chat and ask all your questions. Also, join us for our ...

Changes in the Management Board of Xenios AG

31. March 2021

The Management Board of Xenios AG, the Heart & Lung Business Unit of Fresenius Medical Care, has been restructured. Effective January 31, 2021, the previous Chair of the Executive Board, Dr. Andreas Terpin, has left the company. The new senior trio on the Management Board will continue Fresenius Medical ...

Events

30. September – 01. October
32nd Virtual ELSO Conference

32nd Virtual Annual Extracorporeal Life Support Organization (ELSO) Conference

Venue
Virtual Congress

02. – 06. October
ESICM LIVES 2021

ESICM LIVES 2021 - European Society Of Intensive Care Medicine

14. – 16. October
EACTS 2021

European Association for Cardio-Thoracic Surgery

27. – 30. October
EPNV 2021

15th European Conference on Pediatric and Neonatal Mechanical Ventilation - Montreux, Switzerland